BridgeBio Pharma, Inc. (BBIO) financial statements and ratios from SEC XBRL: revenue $0.7B (TTM), net margin -146.0%, revenue growth 120.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $502.08M |
| Revenue (TTM) | $0.7B |
| Net Margin | -146.0% |
| Operating Margin (TTM) | -69.8% |
| Net Debt / EBITDA | -4.0 |
| Revenue Growth (YoY) | 120.4% |
| EPS Growth (YoY) | -17.9% |
| FCF Growth (YoY) | -12.0% |
| Price / Sales | 22.23 |
| FCF Yield | -2.7% |
| Altman Z-Score | -3.24 (distress) |
| Piotroski F-Score | 2/9 |
| Piotroski checks passed | 2 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.1 |
| Sector P/E (Healthcare) | 21.7 |
BBIO overview · BBIO earnings · BBIO KPIs · BBIO documents · BBIO ownership · BBIO peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.